Circulating tumor cells as prognostic biomarkers for recurrence of breast cancer

Sarah Anwar, MDLinx

San Antonio Breast Cancer Symposium 2017

San Antonio, Texas, United States | December 05-09, 2017

At the 2018 Best of San Antonio Breast Cancer Symposium-New York, Joseph Sparano, MD, professor of medicine and women’s health, Albert Einstein College of Medicine, associate chairman for clinical research, Department of Oncology at Montefiore Medical Center, and associate director for clinical research, Albert Einstein Cancer Center, revisited his team’s findings from ECOG-ACRIN trial, which were originally presented at the Symposium in San Antonio.

Dr. Sparano’s research explored the association between circulating tumor cells and late recurrence in early stage breast cancer. This trial enrolled a subset of patients who were previously enrolled in the E5103 trial, “which was a high-risk population that included patients with a node-positive disease, or high-risk node-negative disease,” between 4.5 and 7.5 years after initial diagnosis of HER2- stage II-III breast cancer, with no clinical evidence of recurrence.

The research group aimed to answer 2 main questions: What is the prevalence of CTC-positivity in the patients? Is the presence of CTC in the blood associated with increased risk of recurrence?

All Interviews

From this Conference

1:11

Breast imaging can predict cancer recurrence
At the 2018 Best of SABCS-NY, Sheldon Feldman, MD, FACS, chief of breast surgery and breast surgical oncology, Montefiore-Einstein Cancer Center, New York, director of breast...
Sheldon Feldman, MD, FACS
4:24

Helping your patient feel in control through effective communication in palliative care
Palliative care is an important tool in helping your patient overcome the stress associated with dealing with their disease and symptoms. Unfortunately, however, there is a...
Thomas J. Smith, MD, FACP, FASCO, FAAHPM
3:14

Managing patients with high risk breast lesions
Amy C. Degnim, MD, professor of surgery, Mayo Clinic, Rochester, MN, discusses the different management strategies for lesions that put patients at increased risk for breast...
Amy C. Degnim, MD

0:52

Value of chemotherapy for patients with locoregional breast cancer recurrence
Although chemotherapy can positively impact patient outcomes after locoregional recurrence of breast cancer, this will generally occur only in patients with HR-negative (HR-)...
William Gradishar, MD
1:47

Evaluating the risk of breast cancer among female patients
There are several factors that put female patients at an increased risk for breast cancer.
Amy C. Degnim, MD
7:15

Seamless designs for clinical trials: A new wave in drug development, explained
With the movement toward developing more targeted therapies, the FDA has updated its drug development system to include what they have designated as ‘seamless...
Tatiana Prowell, MD

This activity is not sanctioned by, nor a part of, the San Antonio Breast Cancer Symposium 2017.